🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Rotarix™

    GlaxoSmithKline

    Infections, Rotavirus

    phase 2 mab completed

    1 trial

  2. Routine Template-based lymphadenectomy

    The First People's Hospital of Lianyungang

    Lymph Node Dissection

    phase 2 other active

    1 trial

  3. Ruxolitinib 5 MG BID Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA

    phase 2 small molecule active

    1 trial

  4. S-337395

    Shionogi B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  5. S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion., S095018/Sym023, S095024/Sym024

    The George Institute

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    phase 2 small molecule active

    1 trial

  6. S230815 Solution for injection 10mg/ml

    The George Institute

    KCNT1-related Developmental and Epileptic Encephalopathy

    phase 2 small molecule active

    1 trial

  7. SA55 Injection

    Sinovac Research and Development Co.,

    Infection of Upper Respiratory Tract Caused by 2019-nCoV

    phase 2 small molecule active

    1 trial

  8. SALBUTAMOL, FLUTICASONE PROPIONATE, NVA237, NVA237, SALMETEROL XINAFOATE, The Placebo is a generic Placebo, inhalation powder, hard capsule. It is used to match an active dosage forms (NVA237 12.5µg and NVA 237 25µg) in this clinical trial. The placebo comprises inactive excipients (magnesium stearate and lactose monohydrate) encapsulated in hard non-gelatin capsules matching those used for the active drug product.

    Novartis Pharmaceuticals

    Asthma

    phase 2 small molecule active

    1 trial

  9. SALINE, OTHER PLASMA PROTEIN FRACTIONS , Octaplasma 45-70 mg/ml pulver og væske til infusjonsvæske, oppløsning, Saline (NaCl)

    Wuhan Createrna Science and Technology Co., Ltd

    Early symptomatic phase Alzheimer's disease

    phase 2 small molecule active

    1 trial

  10. SAR440340

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  11. SAR440340

    Sanofi Pasteur

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  12. SBRT combined with PD-1 inhibitors and thoracic hyperthermia

    The First People's Hospital of Lianyungang

    Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC

    phase 2 other active

    1 trial

  13. SDZ MSL-109

    Ultragenyx UK Limited

    Cytomegalovirus Infections

    phase 2 small molecule completed

    1 trial

  14. SHR-1139 Injection

    The First People's Hospital of Lianyungang

    Pyoderma Gangrenosum

    phase 2 small molecule active

    1 trial

  15. SHR-A1921 injection and adebrelimab injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  16. SKB103 for injection monotherapy

    Sichuan Provincial People's Hospital

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  17. SMT19969

    Summit Therapeutics

    Clostridium Difficile Infection

    phase 2 small molecule completed

    1 trial

  18. SODIUM CHLORIDE , DII235

    Novartis Pharmaceuticals

    Cardiovascular risk reduction in participants with elevated Lp(a)

    phase 2 small molecule active

    1 trial

  19. SOF

    Gilead Sciences Ireland UC

    HCV Infection

    phase 2 small molecule completed

    1 trial

  20. SOF

    Gilead Sciences Ireland UC

    Hepatitis C Virus Infection

    phase 2 small molecule completed

    1 trial

  21. SOLDESAM 0,2% gocce orali, soluzione, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, SOLDESAM 8 mg/2 ml soluzione iniettabile, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules

    Fondazione Telethon ETS

    Multiple Myeloma relapsed and/or refractory

    phase 2 small molecule active

    1 trial

  22. SOX Chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  23. SPD503 (Guanfacine HCl)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  24. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources